Abstract
We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria, 18 with benign urological conditions and 20 healthy subjects. Overall sensitivity and specificity of NMP22 with reference value of 10U/ml was 72 and 73%, respectively. Sensitivity for pT1 and pT2 tumors was 83%, whereas that for pTa tumors was 55%. When the test was determined before and after transurethral resection (TUR) of bladder tumor, it was shown that the TUR effected the NMP22 level. Urinary NMP22was highly sensitive for high-risk bladder cancer. However, the sensitivity of the test is somewhat lower in low grade and stage tumors. Additionally,the effect of previous resection limits its value in the follow up of patients with superficial tumors. The larger series with longer follow up may lead us to determine the time to neglect the effect of TUR on NMP22 and the test kit should be upgraded by the manufacturer to exclude the false positive results due to inflammatory conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
England HR, Paris AMI, Blandy JP. The correlation of T1 tumor history with prognosis and follow-up requirements. Br J Urol 1981; 53: 593.
Murphy WM, Soloway MS, Jukkola AF: Urinary cytology and bladder cancer. Cancer 1984; 53: 1555.
Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of urinary tract. J Urol 1996; 156: 1280.
Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis, DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363.
Berezney R and Coffey DS. Identification of a nuclear protein matrix. Biochem Biopphys Res Commun 1974; 60: 1410.
Pardoll DM, Vogelstein B and Coffey DS. A fixed site of DNA replication in eukaryotic cells. Cell 1980; 19: 527.
Zeitlin S, Parent A, Silverstein S, Efstratiades A. Pre-mRNA splicing and the nuclear matrix: Mol Cell Biol 1987; 7: 111.
Gordon JN, Shu WP, Schlussel RN. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res 1993; 53: 4971.
Nakayasu H and Berezney R. Mapping replicational sites in the eukaryotic nucleus. J Cell Biol 1989; 108: 1.
Keese SK, Briggman JV, Thill G. Utilization of nuclear matrix proteins for cancer diagnosis. CRC Crit Rev Eukaryotic Gene Exp 1996; 6: 189.
Miyanaga N, Akaza H, Ishikava S, Ohtani M. Clinical evaluation of nuclear protein matrix 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Öge, Ö., Atsü, N., Kendi, S. et al. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 32, 367–370 (2001). https://doi.org/10.1023/A:1017509418440
Issue Date:
DOI: https://doi.org/10.1023/A:1017509418440